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Summary: With the aim of revealing a possible magnesium (Mg) deficiency in the aetiology of idiopathic recurrent
calcium urolithiasis we studied the Mg content of red blood cells, serum total, protein-bound, ionised and complexed
fractions of Mg, and urinary Mg after an overnight fast. The two study groups comprised 12 male recurrent calcium
urolithiasis patients and 12 healthy male controls (mean age 31 and 29 years, respectively). In recurrent calcium
urolithiasis, serum albumin and Mg of erythrocytes were significantly decreased, as was serum total and protein-
bound Mg, whereas serum ultrafiltrable, ionised and complexed Mg were statistically indistinguishable from values
in controls. Urinary Mg (per unit creatinine) in recurrent calcium urolithiasis (mean 0.188 vs 0.209 in controls;
p = 0.386) was not statistically different, whereas urinary total protein, glucose, and pH were significantly
increased. The renal clearances of Mg and glucose were positively correlated (r = 0.56; p < 0.01), with a steeper
slope in recurrent calcium urolithiasis than controls. Further fractionation of serum and urinary Mg into ions
and complexes in recurrent calcium urolithiasis subjects with identical creatinine clearance revealed no statistical
difference between
1) Mg ions and complexes filtered by renal glomeruli;
2) Mg ions and complexes excreted in urine;
3) fractional Mg excretion.
Median urine supersaturation with respect to calcium oxalate was insignificantly lower (1.5 vs 2.2), with respect to
hydroxyapatite insignificantly higher (3.3 vs 1.8), than in controls.
It is concluded that relatively young recurrent calcium urolithiasis patients exhibit a deficiency of Mg in erythrocytes
and serum total Mg, but no alteration of renal Mg handling. Thus, in recurrent calcium urolithiasis, a role of Mg
deficiency in urine as a factor initiating stone formation may be ruled out, whereas a possible link between cellular
Mg deficiency and the impairment of renal tubular functions involved in reabsorption of glucose and proteins, and
in urine acidification, deserves further studies.
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respect to sex, age, body mass index, or lean body mass,
' the latter two as measures of obesity. Overweight is a
') Supported by the Erlangen University Hospital research funds, ~ „ ~ . . . . .
and the Division of Research and Development, Madaus, Co- frequent feature of males with recurrent calcium uro-
logne; Germany lithiasis (15), and since these variables have a significant
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association with Mg deficiency (16), studies on Mg that
neglect this may be seriously biased. Furthermore,
because urinary Mg and the renal handling of Mg de-
pend on the body stores of Mg, extracellular Mg in-
cluded, it is essential that cellular content, serum .frac-
tions, and urinary content of Mg are investigated to-
gether. Since urinary Mg acts predominantly in its io-
nised form as an inhibitor of calcium oxalate crystal
growth, renal handling of serum Mg, separately for io-
nised and complexed Mg filtered by glomeruli, is of ma-
jor interest; similarly, also in urine, total Mg should be
considered separately as free ions and complexes. Such
work has not been carried out up to now in renal calcium
stone research.
The present work was conceived as a pilot study with
the aim of identifying a possible Mg deficiency in recur-
rent calcium urolithiasis by means of assessing the fast-
ing Mg content of red blood cells, the biological frac-
tions of Mg in serum, and the concomitant urinary
excretion of Mg.
Materials and Methods
Study participants and procedures
Informed consent was obtained from all participants. Twelve male
recurrent calcium urolithiasis patients (mean age 31 years, range
19—43) and twelve male healthy subjects (mean age 29 years,
range 23—43) were studied, the latter serving as controls. The
study participants were ambulatory, and all were on their usual
home diet until 6:00 p. m. on the day before they entered the hospi-
tal.
In recurrent calcium urolithiasis, the absence of disorders charac-
terised by concomitant stone formation, such as primary hyperpara-
thyroidism, renal tubular acidosis, oxalosis, enteric hyperoxaluria,
or gout was verified. Also, subjects with hypertension, diabetes,
hyperfhyroidism, or urinary tract infection were excluded. The du-
ration of stone disease ranged from 2 months to 29 years. Stone
analysis revealed calcium oxalate in nine, mixed stones (calcium
oxalate plus calcium phosphate) in two, and some indeterminate
calcium salt in one. At the time of laboratory examination (see
below) stones were present in 7 of the 12 recurrent calcium uro-
lithiasis patients.
The order of magnitude of several anthropometric and metabolic
quantities was similar, and the mean values were as following:
body mass index was 23.9 [recurrent calcium urolithiasis] and 22.7
[controls] kg/(cm)2;
serum creatinine 80.3 [recurrent calcium urolithiasis] and 85.5
[controls] μιηοΐ/ΐ;
serum glucose 4.76 [recurrent calcium urolithiasis] and 4.79 [con-
trols] mmol/1;
plasma citrate 0.11 [recurrent calcium urolithiasis] and 0.11 [con-
trols] mmol/1;
the median urinary sodium was 7.83 [recurrent calcium urolithi-
asis] and 7.70 [controls] mol/mol urinary creatinine.
The latter value makes it unlikely that excess salt had been taken
by recurrent calcium urolithiasis patients with the daily home diet.
In both patients and controls, serum potassium and blood gases
were within normal limits, the creatinine clearance exceeded 1 ml/
min · kg body weight, the fasting urinary calcium/creatinine ratio
was normal (< 0.34 mmol/mmol creatinine), except for three re-
current calcium urolithiasis patients who showed fasting hypercal-
ciuria but whose other quantities were within the range of the nor-
mocalciuric stone formers. None of the participants was hyperoxa-
luric (upper limit of normal in this laboratory 0.39 mmol per day),
and none was on long-term anti-stone medication or using any
daily Mg supplementation via food or drinks.
On the day of the examination the following steps [part of a stan-
dardised programme developed to investigate disturbances of min-
eral metabolism (17) and yielding reproducible results upon repeat
application (unpublished data)] were taken in the clinical labora-
tory after an novernight 12-14 h fasting period: 7:30 a. m. bladder
voiding, stimulation of mild diuresis (appro*/1 ml urine per min-
ute) by drinking demineralised water, followed by collection of a
timed (2 h) fasting urine, puncture of a forearm vein and aspiration
of blood without statis.
Physical exercise during the laboratory procedure was kept to a
minimum in all participants to rule out unspecifically stimulated
proteinuria (18).
Analyses
Routine methods were employed for blood gases (Blood Gas Ana-
lyser, Instrumentation Laboratory, Milan; Italy), urinary pH (pH
meter 691, Metrohm, Filderstadt, Germany), and creatinine, so-
dium, potassium (Autoanalyser 747, Hitachi, Japan), calcium (by
complexometry, using Calcium analyser 940, Corning, Halstead;
UK) and phosphorus (as inorganic phosphate, Kit No. 3331, Merck,
Darmstadt; Germany) in serum and urine. Oxalate in urine was
measured by ion chromatography (19). Additional variables inves-
tigated were haematocrit, total protein [in serum by refractometry,
in urine by colorimetry (reagents from Βίο-Rad Laboratories, Mu-
nich; Germany)], albumin [in serum by colorimetry, in urine by
nephelometry (using the monoclonal antibody, OSAL 14, Behring,
Marburg; Germany)]. Atomic absorption spectrophotometry [FL 6,
Zeiss, Oberkochen; Germany (inter-assay coefficient of variation
= 0.6%, based on n = 29 control serum samples)] was used to
determine undiluted serum Mg, Mg in ultrafiltrate of anaerobically
handled serum samples [pressure filtration (nitrogen, 3 bars)
through a A/r 10000 cellulose triacetate membrane; Sartorius,
G ttingen, Germany], and Mg in heparinised plasma and whole
blood, containing 17—20 · 103 IU Na-heparin per litre sample. Io-
nised Mg in heparinised whole blood was determined using a sensi-
tive electrode (CRT 8, Nova Biochemical, Rodermark; Germany),
as described by Altura et al. (20). Serum human intact parathyroid
hormone was measured using a commercial kit (Nichols, Bad
Nauheim; Germany). Serum and urinary citrate (21), and serum
and urinary glucose (Glucose Analyser 2, Beckman, Fullerton;
USA) were determined enzymatically.
Calculations and statistics
The concentration of Mg in erythrocytes (expressed in mmol/1) was
calculated as
P + [100 (W-P) : H],
where P is plasma Mg,
W is Mg in haemolysed whole blood, and
H is the haematocrit (22).
The serum protein-bound and the complexed Mg fractions were
taken as the difference between the concentration of the serum total
and ultrafilterable fraction, and the serum ultrafiltrable and ionised
fraction, respectively. The renal filtered load of total Mg, Mg ions,
and Mg complexes was taken as the product of the respective con-
centration in the ultrafiltrate and the creatinine clearance. Equil-2
software (23) was used for the calculation of urinary ionised and
complexed Mg, and the relative supersaturation products of
calcium oxalate, brushite, and hydroxyapatite in urine. To prevent
errors in bladder voiding, substances in urine were factorised for
urinary creatinine. The results in urine are expressed as arithmetic
means (range), in blood as arithmetic means (SEM), if not other-
wise indicated. Differences between groups were tested for signifi-
cance (p < 0.05) by the t- or U-test, as appropriate. For several
variables Spearman*s correlation coefficient was assessed.
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Tab. 1 Baseline clinical chemistry data of patients with recurrent
calcium urolithiasis and controls (healthy non-stone-forming indi-
viduals). Mean values (SEM, or range of values). S: serum; P:





















































































































The baseline clinical chemistry data in recurrent calcium
urolithiasis patients and controls, matched for sex, age,
body mass index, renal function (see Material and Meth-
ods), are shown in table 1. Except for serum albumin,
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Fig. 1 Interrelationship of the clearances of total magnesium and
glucose in fasting urine of male recurrent calcium urolithiasis
patients (A; n = 12) and healthy controls (Ο; η = 11). The dashed
line denotes that ih the rnajority of recurrent calcium urolithiasis
subjects glucosuria is > 0.046 ml/min. For further details see text.
asis was 4.4 per cent less than in controls, there were no
statistically significant differences detectable in serum
or plasma.
In fasting urine of recurrent calcium urolithiasis patients,
the pH was significantly elevated, as were protein and
glucose; the creatinine clearance, albumin, sodium, and
potassium all tended to show higher, phosphate and Mg
lower values than in controls. The degree of proteinuria
and albuminuria was not different between recurrent
calcium urolithiasis patients with stones in situ and those
without stones at the time of examination. There was a
significant positive correlation between the urinary
clearances of Mg and glucose (r = 0.56, p < 0.01), with
a steeper slope of the regression line for the patients
(n = 12, r = 0.62, slope = 0.03) than for the controls
(n = 11, r = 0.575, slope = 0.006) (fig. 1). Applying a
cut-off point of 0.046 ml/min glucose clearance to the
plot largely separates the two groups, only a single indi-
vidual being definitively common to both. No other cor-
relations with urinary glucose as the dependent variable
could be detected.
Mg in erythrocytes, biological Mg fractions
(tab. 2)
Mg in erythrocytes of recurrent calcium urolithiasis pa-
tients was about 9.5% lower than in controls, with the
difference being very close to the level of significance
(for reference values see 1. c. (24, 25)). Also in recurrent
calcium urolithiasis, the serum total and protein-bound
Mg concentrations were about 7 and 13% lower
(p < 0.05, and of borderline significance, respectively),
and the mean values of ultrafilterable and ionised Mg
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Tab. 2 Magnesium (Mg) in red blood cells and Mg fractions in
serum, all in mmol/1, of stone patients and healthy subjects (con-
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were each about 5% lo\ver than in controls. In both re-
current calcium urolithiasis and controls the protein-
bound and ultrafilterable Mg concentrations as a percen-
tage of total serum Mg were similar to those reported
for healthy individuals (25). There was no significant
correlation between erythrocyte Mg and serum total Mg
(recurrent calcium urolithiasis, n = 12, r = 0.092,
p = 0.789; controls, n = 12, r = 0.296, p = 0.351) or
ultrafilterable Mg (recurrent calcium urolithiasis,
n = 12, r = 0.140, p = 0.681; controls, n = 12,
r = 0.331, p = 0.294).
Ur inary Mg, protein and glucose at
comparable creat inine clearance in recurrent
calcium uro l i th ias i s and controls (tab. 3)
To rule out the possibility that differences in the filtered
load of Mg interfere with the amount of Mg in the final
urine, we selected eight individuals from each of the
twelve recurrent calcium urolithiasis patients and con-
trols, who had almost identical creatinine clearance. This
resulted in practically the same values for the Mg excre-
tion rate and urinary Mg/creatinine ratio in recurrent
calcium urolithiasis and controls; also with all other Mg
variables studied significant difference between the
groups. However, in recurrent calcium urolithiasis, the
excretion rate of free Mg ions was slighly higher, and
that of complexed Mg slightly lower than in controls; in
addition, the mean fractional clearance of total and io-
nised Mg in these eight recurrent calcium urolithiasis
patients was also higher, indicating the presence of some
factor able to influence net tubular reabsorption of Mg.
Urinary protein was 3.3-fold higher, and urinary glucose
2.8-fold higher in recurrent calcium urolithiasis patients
than in controls.
State of supersaturation of urine (tab. 4)
In recurrent calcium urolithiasis as a whole group (12
patients) the mean relative supersaturation products of
calcium oxalate was apparently lower than in controls
(12 subjects), the difference being of borderline signifi-
cance. In contrast, the mean relative supersaturation
products of hydroxyapatite in recurrent calcium uro-
lithiasis was 1.8- to 2-fold higher than in controls, due
mainly to their higher urinary pH (see table 1), whereas
Tab. 3 Renal handling of magnesium (Mg) in 8 recurrent calcium
urolithiasis patients and controls, respectively, with comparable
mean creatinine clearance (as a marker of glomerular filtration
rate). Mean values (range). Fractional excretion is synonymous
with fractional clearance. For other abbreviations and details see
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Tab. 4 Relative supersaturation products for calcium oxalate, brushite, and hydroxyapatite in recurrent
calcium urolithiasis patients and controls, respectively. Mean values (range).





















*: free energy (see 1. c. (22))
the mean relative supersaturation product of brushite
was comparable in recurrent calcium urolithiasis and
controls.
Discussion
Current understanding of Mg status in
recurrent calcium uroli thiasis
We assessed the Mg status in male recurrent calcium
urolithiasis patients, strictly matched with controls for
age, weight, and body mass, and we included in the ex-
amination erythrocyte Mg, serum total Mg and its pro-
tein-bound, ultrafilterable, ionised, and complexed frac-
tions, as well as ionic and complexed urinary Mg. Ery-
throcyte Mg was examined because Mg concentration in
these cells is genetically controlled (26), and therefore
is largely independent of intestinal Mg uptake and acute
changes in extracellular Mg (see below). Furthermore,
the Mg content of nuclei-containing skeletal muscle
cells did not differ between renal stone patients and
healthy controls (12). Thus, in the synopsis our data
probably correctly reflect the Mg status during the cho-
sen time segment of a daily cycle, viz., 2 hours in the
morning, after a prior 12—15 hours nocturnal fast.
The frequency of recurrent calcium urolithiasis is great-
est in the fourth and fifth decade of life (27), with a
maximum around the age of 40 years. Our data on Mg
demonstrate that even younger recurrent calcium uro-
lithiasis patients exhibit signs of an impaired Mg status.
This situation may have escaped detection by previous
investigators, because age was not conceived as a possi-
bly biasing factor (12, 13). Thus, in our laboratory, male
normocalciuric patients older than 40 revealed similar
tubular handling of Mg, yet there was no evidence of Mg
deficiency in erythrocytes or serum (unpublished data);
independency of blood cell and total serum Mg from
age was also found for healthy humans (28). However,
intestinal transport of Mg decreases with age, but is
maintained at near normal levels at the expense of regu-
latory hyperparathyroidism (29), thereby masking the
presence of a generalised abnormal Mg status.
Another reason for the discrepant data on the state of
Mg, especially magnesiuria, in the literature (for review
see 1. c. (14)), maybe sought in the degree of the associ-
ated calciuria. Thus, many hypercalciuric stone patients,
who show a filtered load of Mg similar to that of normo-
calciuric stone patients, are unable to increase Mg reab-
sorption appropriately; consequently they excrete even
more Mg than controls (unpublished data). Similar find-
ings were reported by others who examined Mg in 4 h
fasting urine and 24 h urine of renal calcium stone pa-
tients (30-33). In the present work three recurrent
calcium urolithiasis patients were classified as having
idiopathic hypercalciuria (see Materials and Methods);
they were not omitted but instead further studied al-
though all Mg values were at the upper limit of the range
observed for the normocalciuric patients.
Magnesium in blood
In the literature the values of erythrocyte Mg in healthy
controls are generally higher, probably due to the use
of different methodology (22, 24). Erythrocyte Mg is
determined during maturation of the erythrocytes in
bone marrow (34). There are conflicting reports regard-
ing the mobility of Mg in erythrocytes. While Mg in
blood cells in general was found to represent a more
mobile pool, in contrast to parenchymatous organs like
the liver and probably the kidney (35), a recent report
states that in human erythrocytes the transmembrane Mg
fluxes are slowed (36).
Consistent with the latter view would be the absence
of a correlation between erythrocyte Mg and serum or
ultrafilterable Mg in both recurrent calcium urolithiasis
and controls (see Results). Therefore, the decrease of
erythrocyte Mg in recurrent calcium urolithiasis as a
whole group may be due to a long-term Mg deficiency
of the whole body, probably resulting from an inade-
quate supply of exogenous Mg rather than enhanced Mg
losses (see also below). Mg depletion of food in Western
civilisation is supected of being one cause of low serum
total Mg (37), and our findings of low serum total and
protein-bound Mg in recurrent calcium urolithiasis
would be compatible with this view. Alternatively, low
serum total Mg as a consequence of impaired intestinal
Mg uptake in recurrent calcium urolithiasis deserves
consideration, but its occurrence in the relatively young
individuals studied by us is unlikely. It should be noted
that although the protein-bound fraction of serum Mg is
reduced in proportion to the low serum albumin (see tab.
1), it is not alone responsible for the low total Mg; to a
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certain extent all serum fractions contribute to the deficit
of total Mg (tab. 2). This situation is similar to that re-
ported by others, in that changes of serum albumin
within the normal limits did not account for changes of
serum total Mg (38).
In controls, the mean value of ionised Mg was about 20
per cent lower than that reported by Altura and co-
workers (25), although in the laboratory of these workers
and our own the same Mg sensitive electrode was used.
The reason for this discrepancy is not readily recogniz-
able. However, the subjects studied by these workers
were on average older [29 years (present work) vs 59,
(25)] and their blood pH was an average higher [7.392
(present work) vs 7.465 (25)], suggesting that either an
age-related increase of free ions in plasma, decreased
complexation or protein-binding of ions, or some combi-
nation of these two effects was responsible (see below).
As these authors (25) provided no further information on
serum total protein, albumin, and citrate, the true state of
ionised Mg, an important biological property, remains
unclear. Free ionised Mg in plasma results from the bal-
ance of Mg bound to macromolecules and complexed
by small molecules, such as citrate or fatty acids. In our
recurrent calcium urolithiasis patients, albumin was low
(tab. 1) and citrate was indistinguishable from controls
(see Material and Methods), so that ionised Mg in recur-
rent calcium urolithiasis should not have been low —
thereby contrasting with the values reported by other
authors (25) — but should have remained normal or even
high. Thus, from the available data, the factor underlying
the mean lower concentration of serum ionised Mg in
recurrent calcium urolithiasis is not discernable, but may
in part reflect the mean higher Mg ion exretion via urine
(see below, and tab. 3).
Renal function and Mg in recurrent calcium
urol i th ias i s
Recurrent calcium urolithiasis patients exhibited a
number of abnormalities so far not generally recognised
(tab. 1; fig. 1). In fasting urine these abnormalities in-
clude hyperproteinuria, hyperglucosuria, less acidic pH,
and a trend toward higher creatinine clearance and
higher albuminuria. Hyperproteinuria and hyperglucosu-
ria persist after correction for creatinine clearance (see
tab. 3). These findings support the contention that some
abnormality of the nephron, be it functional, morpholog-
ical, or both, is present in recurrent calcium urolithiasis.
In searching for the origin of these, a somewhat disor-
dered Mg, or some other disorder not studied here, may
be considered as the critical factor(s).
Dietary Mg deficit is discussed as causing abnormalities
in blood lipids in the rat (39), and disturbances of lipids
are a constant feature of kidney diseases in humans, es-
pecially glomerular lesions (40). Thus, lipid-induced but
Mg-dependent injury of both glomeruli and tubules
might exist in the recurrent calcium urolithiasis patients
in the present work, and may have facilitated the appear-
ance in urine of proteins, whose access to the tubular
lumen is normally prevented by intact tissues. On the
other hand, the composition and metabolism of lipids
may be primarily altered in recurrent calcium urolithi-
asis (41); also alteration of lipids has been discussed as
one possible cause of increased Mg retention, which
itself reflects the body's need to conserve Mg (42). Work
related to such possibilities is currently in progress in
our laboratory.
With the technical tools presently available it is not fea-
sible to probe in situ, i. e. inside renal tubular cells, the
state of Mg, to determine the cytosolic free Mg ion con-
centration or the concentration of Mg bound to subcellu-
lar structures. If low erythrocyte Mg reflects low renal
cell Mg, regardless of the aetiology of Mg deficit, then
events adversely affecting intracellular processes may be
the consequence. Cellular Mg deficiency would lead to
impaired phosphorylation due to the uncoupling of Mg-
substrate binding, thereby preventing the reaction of the
complex with hexokinase (43, 44), the key enzyme in
transmembrane flux of (phosphorylated) glucose. Thus,
in our recurrent calcium urolithiasis patients without
overt signs of diabetes and insulin deficiency, the
increased glucosuria should arise from decreased glu-
cose uptake by the luminal structures of proximal tubu-
lar cells. Moreover, inappropriately high phosphaturia,
as was found in Mg-deficient rats devoid of parathyroid
glands (45), should also occur in recurrent calcium uro-
lithiasis with normal parathyroid gland function; in the
long-term such a situation should lead to some degree
of phosphate deficiency. In fact, the latter may be recog-
nised in both the low phosphate of fasting serum (46)
and low urinary phosphate (46, 47; this work); both of
these phenomena are lesser known features of recurrent
calcium urolithiasis, as is exaggerated phosphaturia in
response to a carbohydrate- and calcium-rich test meal,
i. e. during a postprandial period with calcium-induced
suppression of the phosphaturic component of parathy-
roid hormone (48).
Mg deficiency causes increased oxidative stress to vari-
ous tissues, reflected in an increased lipid peroxidation
(49, 50). One of the manifestations of oxidative stress is
injury to endothelial cells (49) and, if Mg deficiency
is severe, loss of the integrity of unspecified renal cell
membranes (50). The steep blood-lumen pH gradient
normally achieved by proton secretion into the distal tu-
bule is linked to the activity of a Mg2+ ATPase of the
lurninal membrane (51). Thus, impaired acidification of
fasting urine in Mg-deficient males with recurrent
calcium urolithiasis (table 1), already previously de-
scribed by us (52), may reflect an inadequate enzyme
activity due to renal tubular cell damage, hence dimin-
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ished proton generation. Viewed together, these interre-
lationships appear to show that Mg deficit is a potential
common denominator of several abnormalities seen in
recurrent calcium urolithiasis.
Calcifications and Mg
In pre-lithotripsy patients we found that the surface of
stones in situ is smaller in the presence of high urinary
Mg ion concentration, and vice versa (53); however,
these patients were older, and obesity and calciuria were
not strictly controlled. In the present work, a role of Mg
in the aetiology of crystals or stones remains uncertain,
considering the unaltered Mg in urine (tab. 3), and the
associated supersaturation products of calcium oxalate
and brushite (tab. 4). However, the higher protein and
the trend to higher albumin in urine of recurrent calcium
urolithiasis may lend research interests into promising
directions. Although the degree of hyperproteinuria is
small, the finding is reminiscent of ̂ reclinical signs in
human individuals at risk of developing atherosclerosis
(see 1. c. (53)) and non-insulin-dependent diabetes melli-
tus, the latter being frequently associated with a cellular
Mg deficit (55). Several proteins bind calcium; hence,
even a small excess of proteins and possibly albumin,
which is a constituent of stone matrix (56), may help to
glue crystals together. The diameter of such crystallised
particles, not single crystals, determines whether ob-
struction of the tubular lumen and formation of micro-
liths occur (57).
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